Craig T. Hartrick

TL;DR: Simultaneous pain measurements using these 2 scales were compared in clinical situations commonly encountered in a tertiary community hospital and no correlations were noted for the same postoperative patients at rest or for postoperative orthopedic patients.

TL;DR: The efficacy and tolerability of tapentadol IR 50 and 75 mg was noninferior to that of oxycodone HCl IR 10 mg; however, the incidence of selected gastrointestinal AEs (nausea, vomiting, and constipation) was significantly lower for both doses ofTapentadl IR compared with oxycod one HClIR 10 mg (nominal P < 0.001).

TL;DR: EREM provided significant postoperative pain relief over a 48-h period after hip surgery, without the need for indwelling epidural catheters, and the safety profile of EREM was consistent with that of other epidurally administered opioid analgesics.

TL;DR: Treatment for patients with severe pain in the chronic phase consists of manual therapy and/or a local injec- tion of local anesthetic and corticosteroid into the painful segment and other interventional treatments such as intradiscal injections, ganglion impar block, radiofrequency treatment and caudal block are advised only under study conditions.

TL;DR: Clinical trial evidence in acute and chronic non-cancer pain and neuropathic pain supports an opioid-sparing effect that reduces some of the typical opioid-related adverse effects for tapentadol, which results in improved tolerability and adherence to therapy for both the immediate- and extended-release formulations of tapENTadol.